News from creative medical technology holdings, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 09, 2021, 08:18 ET Creative Medical Technology Holdings Identifies Synergy Between ImmCelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

Creative Medical Technology Holdings, trading under Ticker Symbol CELZ, announced the filing of a provisional patent application in connection with...

May 24, 2021, 07:45 ET Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

Creative Medical Technology Holdings, trading under ticker symbol CELZ, announced today positive preclinical data supporting extension of ImmCelz®...

May 20, 2021, 08:45 ET Internationally Renowned Clinician Scientist Camillo Ricordi Head of Diabetes Research Institute Joins Creative Medical Technology Holdings

Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company's Scientific Advisory Board. Dr. Ricordi will...

May 14, 2021, 07:45 ET FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz® IND for Stroke Treatment

Creative Medical Technology Holdings Inc., trading under ticker symbol CELZ, announced today receipt of detailed correspondence from the FDA...

Mar 23, 2021, 07:45 ET Creative Medical Technology Holdings, Inc. to Launch Virtual Physician™ Focused on Telehealth Solutions for Regenerative Medicine

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...

Mar 16, 2021, 07:15 ET Creative Medical Technology Holdings, Inc. Announces FDA Acknowledgment of IND Application for ImmCelz® to Treat Stroke

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...

Mar 10, 2021, 07:45 ET Creative Medical Technology Holdings, Inc. Begins Recruitment of StemSpine® Clinical Sites

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...

Mar 04, 2021, 07:45 ET Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine® Personalized Adult Stem Cell Therapy

(OTC - CELZ) Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15...

Mar 03, 2021, 07:15 ET Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application

(OTC-CELZ) Creative Medical Technology Holdings announced today that due to COVID related technical changes in the FDA's submission requirements, the ...

Feb 16, 2021, 07:45 ET Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection using ImmCelz®

(OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today filing of a patent application covering the use of ImmCelz® regenerative cell ...

Feb 10, 2021, 07:45 ET Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented OvaStem® Female Infertility/Ovarian Failure Treatment

(OTC-CELZ) Creative Medical Technology Holdings announced today new data explaining mechanisms of action of its patented OvaStem® female...

Feb 08, 2021, 07:45 ET Creative Medical Technology Holdings Recruits Internationally Renowned Kidney Expert to Scientific Advisory Board

(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Caigan Du, Associate Professor at the University of British...

Feb 01, 2021, 07:45 ET Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of ImmCelz® Therapeutic Activity

(OTC – CELZ) Creative Medical Technology Holdings, Inc. announced today new data demonstrating that administration of ImmCelz® to animals with a...

Jan 27, 2021, 07:45 ET Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz® Regenerative Immunotherapy

(OTC-CELZ) Creative Medical Technology Holdings announced today filing of a patent application disclosing new data in which the ImmCelz® Regenerative ...

Jan 21, 2021, 08:15 ET Creative Medical Technology Holdings Recruits Founder of Inc 500 Clinical Trials Company Dr. Boris Reznik to Accelerate Development of ImmCelz® Through FDA

(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Boris Reznik to the Company's Scientific Advisory Board. Dr....

Jan 20, 2021, 08:15 ET Leading Urologist Doubles Down on CaverStem® Regenerative Stem Cell Procedure for Treatment of Erectile Dysfunction in Men

Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to...

Jan 19, 2021, 07:45 ET Creative Medical Technology Holdings Announces Positive Data and Patent Filing Using ImmCelz® to Treat Type 1 Diabetes

(OTC: CELZ) Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz® in...

Jan 12, 2021, 08:15 ET Creative Medical Technology Holdings Files Investigational New Drug Application (IND) with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy

(OTC - CELZ) Creative Medical Technology Holdings Inc. announced today filing of an Investigational New Drug (IND) application with the Food and Drug ...

Jan 06, 2021, 07:45 ET ImmCelz® Stem Cell Component Demonstrated Efficacious in FDA Double Blind Placebo Controlled Clinical Trial of Advanced COVID-19 Patients

Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami demonstrating that ...

Dec 31, 2020, 07:45 ET Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz® Regenerative Immunotherapy

(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz® in treatment of a model of heart...

Dec 29, 2020, 07:45 ET Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz® Personalized Cellular Immunotherapy in Preclinical Model

(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today novel data and patent filing No. 63131261 describing the ability of ImmCelz® to...

Dec 22, 2020, 07:45 ET Creative Medical Technology Holdings Identifies Mechanism of Action of ImmCelz® Stroke Regenerative Activity

Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today data identifying one of the primary mechanisms of action of its ImmCelz®...

Dec 16, 2020, 07:45 ET Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke

Creative Medical Technology Holdings Inc., (OTC – CELZ) announced today positive preclinical data supporting the utilization of its ImmCelz® cell...

Dec 10, 2020, 07:45 ET Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the ...

Sep 29, 2020, 08:15 ET Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model

(OTC-CELZ) -- Creative Medical Technology Holdings announced today proof of concept studies demonstrating efficacy of its ImmCelz® immunotherapy...